Information to be requested from all CA17104 participants:

 Photo	
Indicate your Working Group(s) in COST Action17104:	Pharmacokinetics and ADMET of the new therapeutic tools; safety of the targets, group 4
First Name:	**Simonida**
Surname:	**Crvenkova**
Department	**Lung cancer department**
Primary Institution	**University Clinic of radiotherapy and oncology, Medical faculty**
Address of Primary Institution	**Mother Theresa 16**
Other institutions	
Telephone:	**+38970338687**

e-mail:	**simonidac@hotmail.com**
Link to webpage with biography:	https://www.pubfacts.com/author/Simonida+Crvenkova
Link to webpage with group description:	

Orcid ID or Scopus ID	**https://www.scopus.com/authid/detail.uri?authorId=12763093300#top**
Linkedin	https://mk.linkedin.com/in/simonida-crvenkova-91980214
Expertise relevant for this COST Action:	An expanded access program of Tarceva (erlotinib) in patients with advanced stage IIB/IV non-small cell lung cancer – coinvestigator Simonida Crvenkova MO18109 2005 - Multicenter, randomized, double-blind, phase III trial to investigate the efficacy and safety of oral BIBF 1120 plus standard pemetrexed therapy compared to placebo plus standard pemetrexed therapy in patients with stage IIIB/IV or recurrent NSCLC after failure of first line chemotherapy- principal investigator- Simonida Crvenkova, 2010-12
Available facilities to conduct work, relevant for this COST Action:	
Matherials/Methods that could be shared with other members of this COST Action:	

NOTE: By submitting this form to the Grant Manager of CA17104, I agree that this information can be used within the scope of this COST Action (e.g. may be included on the webpage of CA17104).